An exhibition of modern art at the National Art Center Tokyo explores how growth at the pan-global scale has also led to lives that are increasingly...
Japan begins increasing individual contributions to the cost of COVID-19 treatment. Is 10% enough? The search is on for a fair balance.
Popular names such as Beyblade and Tamagotchi brought new toys and state-of-the-art designs to the floor of the International Tokyo Toy Show in Koto ward.
After nearly 7 million deaths, Tedros has declared the crisis is over. But WHO's deference to China and the origins of COVID-19 have yet to be...
Many tourists from Japan and overseas returned to Himeji Castle in spring 2023 to enjoy the cherry blossoms on one of the country's most famous castle...
We have seen COVID-19 gradually weaken in Japan over time. It is now time to move into a new and healthy future, without the pandemic-fueled burden...
Reclassifying COVID-19 as seasonal flu, the Japanese government should clarify how it would respond in the event of risk of increased infections and deaths.
Weary of China's zero-COVID humanitarian havoc, and the world's ambivalence, China's own citizens took the responsibility of making their voices heard.
There is a shocking contrast between the COVID-19 case numbers and deaths announced by Beijing compared to local regions in China.
China’s zero-COVID policy, which features strict local lockdowns, has caused economic activity to slump. The Chinese public is losing patience.
Relying on Xocova alone is not enough. It should be used with other available drugs according to their characteristics to suppress a resurgence of COVID-19.
Shionogi's Xocova is Japan's first domestically produced COVID drug to gain approval for practical use as preparation gear up for the "eighth wave."
